CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals
Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped…
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
